SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (8776)2/18/1999 10:29:00 AM
From: Robert K.  Respond to of 17367
 
George, I asked that question, and I noted uncertainty. Its IMO.
Here is something that may indirectly affect hu1124

>SOUTH SAN FRANCISCO, Calif.---Feb. 18, 1999-- Genentech, Inc. (NYSE:GNE - news), announced today that the 178-patient Phase II clinical trial of the company's recombinant human vascular endothelial growth factor (rhVEGF165) protein did not meet its primary objectives.

''Based on the interesting biology of rhVEGF165, we are disappointed in the preliminary view of the data,'' '

Genentech plans to meet with its rhVEGF165 investigators to determine next steps for the development of the molecule.



To: aknahow who wrote (8776)2/18/1999 10:17:00 PM
From: ewolf  Read Replies (1) | Respond to of 17367
 
I'm almost positive that you know now that Xoma's fourth quarter statement won't be announced until next week as indicated on their web site. But then, I'm not absolutely sure.(you know)


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News